--- title: "Mangoceuticals (MGRX) news: offering" url: "https://aibio.space/companies/mangoceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MGRX offering news: Mangoceuticals sells 709,677 shares at $1.55 in $1,100,000 private placement. Mangoceuticals, Inc. (NASDAQ: MGRX), United States." --- MGRX Mangoceuticals, Inc. NASDAQ · United States # Mangoceuticals (MGRX) news MGRX offering news Mergers · 2026-10-01 ## [Mangoceuticals unit MangoRx IP gets $2.5 million commitment, receives $1.75 million](https://aibio.space/news/mangoceuticals-unit-mangorx-ip-gets-2-5-million-commitment-receives-1/) Two strategic investors paid the first $1.75 million tranche for a 17.5% interest in MangoRx IP, a former subsidiary of Mangoceuticals. The other $750,000, for 7.5%, is due by November 28, 2026, and the company's cash had fallen to $228,688 by June 30. ## Latest Mangoceuticals news 1. 2025-09-02 Financings [Mangoceuticals sells 709,677 shares at $1.55 in $1,100,000 private placement](https://aibio.space/news/mangoceuticals-sells-709-677-shares-1-55-1-100-000-private-placement/) Five accredited investors bought restricted stock under subscription agreements signed August 26, 2025 and August 29, 2025. No underwriters were used. ## Mangoceuticals at a glance - **Ticker**: MGRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $228,688 ### Related companies - [Electra Therapeutics](https://aibio.space/companies/electra-therapeutics/) NASDAQ: ETRA - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) NASDAQ: CPIX - [Azitra](https://aibio.space/companies/azitra/) AMEX: AZTR - [Tonix Pharmaceuticals Holding](https://aibio.space/companies/tonix-pharmaceuticals/) NASDAQ: TNXP - [Ironwood Pharmaceuticals](https://aibio.space/companies/ironwood-pharmaceuticals/) NASDAQ: IRWD - [Damora Therapeutics](https://aibio.space/companies/damora-therapeutics/) NASDAQ: DMRA - [Collegium Pharmaceutical](https://aibio.space/companies/collegium-pharmaceutical/) NASDAQ: COLL - [ANTHERA PHARMACEUTICALS INC](https://aibio.space/companies/anthera-pharmaceuticals/) OTC: ANTH ### Also on NASDAQ - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) ASMB - [TANDEM DIABETES CARE INC](https://aibio.space/companies/tandem-diabetes-care/) TNDM - [BioNTech](https://aibio.space/companies/biontech/) BNTX - [Revelation Biosciences](https://aibio.space/companies/revelation-biosciences/) REVB - [Beam Therapeutics](https://aibio.space/companies/beam-therapeutics/) BEAM - [Citius Oncology](https://aibio.space/companies/citius-oncology/) CTOR ## What Mangoceuticals does Mangoceuticals, Inc. connects consumers to licensed healthcare professionals through its website, MangoRX.com, for care via telehealth on its customer portal. It focuses on developing, marketing and selling men's wellness products and services through a telemedicine platform, particularly in erectile dysfunction, hair loss, testosterone replacement or enhancement therapies and weight management. The company is commercially marketing compounded products under the brand names Mango for erectile dysfunction, Grow for hair loss, Mojo for hormone balance and therapy, and Slim for weight loss. The compounded products are produced and fulfilled by Epiq Scripts, LLC, a related party compounding pharmacy that is 52% owned by Jacob Cohen, the company's Chief Executive Officer and Chairman. The compounded products are available to patients when a prescribing physician determines the compounded drug is necessary for the individual patient. The company also uses Epiq Scripts to fulfill all patient orders of its Prime product. | Product or program | What it is | Stage | |---|---|---| | Mango | Compounded erectile dysfunction product | commercially marketed | | Grow | Compounded hair loss product | commercially marketed | | Mojo | Compounded hormone balance and therapy product | commercially marketed | | Slim | Compounded weight loss product | commercially marketed | Summarised from the company's [10-K filed Apr 1, 2026](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/form10-k.htm). ## Mangoceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$456,021](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/) | [$615,873](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/) | | Net income (loss) | [-$20.6 million](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/) | [-$8.7 million](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/) | | Cash from operations | [-$5.9 million](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/) | [-$4.9 million](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/) | | Cash and equivalents | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/) | [$58,653](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $228,688. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Mangoceuticals Has Mangoceuticals raised money recently? Our latest story on this, dated Sep 2, 2025: "Mangoceuticals sells 709,677 shares at $1.55 in $1,100,000 private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/mangoceuticals-sells-709-677-shares-1-55-1-100-000-private-placement/). What is the ticker symbol of Mangoceuticals? Mangoceuticals, Inc. trades under the ticker MGRX on NASDAQ. Where is Mangoceuticals listed? Mangoceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Mangoceuticals? The SEC Central Index Key (CIK) for Mangoceuticals, Inc. is 1938046. Its filings are on SEC EDGAR. How many shares does Mangoceuticals have outstanding? 21,567,422 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Mangoceuticals listed under? Our directory records Mangoceuticals, Inc. under United States. What does Mangoceuticals do? Our directory classifies Mangoceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Mangoceuticals? The ISIN recorded for Mangoceuticals, Inc. is US56270V2051. Does aibio.space cover Mangoceuticals? aibio.space lists Mangoceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Mangoceuticals incorporated? SEC records list its state or country of incorporation as TX. What does Mangoceuticals develop? Mangoceuticals, Inc. connects consumers to licensed healthcare professionals through its website, MangoRX.com, for care via telehealth on its customer portal. It focuses on developing, marketing and selling men's wellness products and services through a telemedicine platform, particularly in erectile dysfunction, hair loss, testosterone replacement or enhancement therapies and weight management. What is Mango from Mangoceuticals? Mango: Compounded erectile dysfunction product Stage: commercially marketed. What is Grow from Mangoceuticals? Grow: Compounded hair loss product Stage: commercially marketed. What was Mangoceuticals's revenue last year? $456,021 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Mangoceuticals profitable? Mangoceuticals, Inc. reported a net loss of $20.6 million for the fiscal year ended Dec 31, 2025, and used $5.9 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Mangoceuticals Members talk about Mangoceuticals (MGRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Mangoceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-01 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226045341/ex99-1.htm) 2. 2026-08-21 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226039724/form8-k.htm) 3. 2026-08-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226035993/ex99-1.htm) 4. 2026-07-30 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226035323/ex99-1.htm) 5. 2026-07-30 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226035324/form425.htm) 6. 2026-07-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226031917/form8-k.htm) 7. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226023883/formnt10-q.htm) 8. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014360/formnt10-k.htm) 9. 2026-02-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226005587/form8-k.htm) 10. 2026-01-13 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315226002093/forms-1.htm) 11. 2025-12-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225028444/ex99-1.htm) 12. 2025-10-29 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225019941/form8-k.htm) 13. 2025-09-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225012557/form8-k.htm) 14. 2025-08-04 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225011557/form8-k.htm) 15. 2025-06-10 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000164117225014545/form8-k.htm) 16. 2025-05-30 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000164117225012917/form8-k.htm) 17. 2025-05-23 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000164117225012336/form8-k.htm) 18. 2025-05-06 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000164117225008878/form8-k.htm) 19. 2025-04-25 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000164117225006122/ex99-1.htm) 20. 2025-04-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225011197/form8-k.htm) 21. 2025-03-20 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1938046/000164117225000085/form10-k.htm) 22. 2025-03-19 Financings Reported a financing. SEC Form 8-K (Items 3.02,3.03,5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225010875/form8-k.htm) 23. 2025-02-19 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225007597/form8-k.htm) 24. 2025-02-07 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225005457/form8-k.htm) 25. 2025-01-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225003054/form8-k.htm) 26. 2025-01-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315225001401/form8-k.htm) 27. 2024-12-19 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315224050830/ex99-1.htm) 28. 2024-12-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315224049133/form8-k.htm) 29. 2024-10-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1938046/000149315224043134/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MGRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-MGRX/). ## SEC filings and registration - **SEC name**: Mangoceuticals, Inc. - **CIK**: 1938046 - **Industry (SIC)**: Services-Misc Health & Allied Services, NEC (8090) - **US tickers**: MGRX (Nasdaq) - **State or country of incorporation**: TX - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 15110 DALLAS PKWY, SUITE 600, DALLAS, TX, 75248 - **Phone**: (833) 626-4679 - **Shares outstanding**: 21,567,422 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: MANGOCEUTICALS, INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1938046/000149315226046510/form8-k.htm) filed 2026-10-09 - [424B5](https://www.sec.gov/Archives/edgar/data/1938046/000149315226046508/form424b5.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1938046/000149315226045341/form8-k.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1938046/000149315226039724/form8-k.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1938046/000149315226035993/form8-k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1938046/000149315226035323/form8-k.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1938046/000149315226031917/form8-k.htm) filed 2026-07-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001938046), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Mangoceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MGRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Mangoceuticals, Inc. - **Ticker**: MGRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US56270V2051 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MGRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/mangoceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Mangoceuticals (MGRX) news: offering", 2026-10-31, https://aibio.space/companies/mangoceuticals/